Biosergen AB (OSTO:BIOSGN) Cash-to-Debt : No Debt ⁽¹⁾ (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Biosergen AB's cash to debt ratio for the quarter that ended in Mar. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Biosergen AB could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Biosergen AB's Cash-to-Debt or its related term are showing as below:

OSTO:BIOSGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 12.21 Med: No Debt Max: No Debt
Current: No Debt

During the past 4 years, Biosergen AB's highest Cash to Debt Ratio was No Debt. The lowest was 12.21. And the median was No Debt.

OSTO:BIOSGN's Cash-to-Debt is ranked better than
99.87% of 1523 companies
in the Biotechnology industry
Industry Median: 6.39 vs OSTO:BIOSGN: No Debt

Biosergen AB Cash-to-Debt Historical Data

The historical data trend for Biosergen AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Biosergen AB Cash-to-Debt Chart

Biosergen AB Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

Biosergen AB Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial									No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Biosergen AB's Cash-to-Debt

For the Biotechnology subindustry, Biosergen AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biosergen AB's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biosergen AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Biosergen AB's Cash-to-Debt falls into.

Biosergen AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Biosergen AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Biosergen AB had no debt ⁽¹⁾.

Biosergen AB's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Biosergen AB had no debt ⁽¹⁾.

Biosergen AB (OSTO:BIOSGN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Biosergen AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Biosergen AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosergen AB (OSTO:BIOSGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (OSTO:BIOSGN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Fogdevreten 2, Solna, SWE, 17165

Website

https://www.biosergen.net

Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.

Biosergen AB (OSTO:BIOSGN) Headlines

No Headlines

Biosergen AB (OSTO:BIOSGN) Cash-to-Debt : No Debt (1) (As of Mar. 2024)